在患有原发性纤毛功能障碍的儿童中,支气管扩展剂的响应性
Elias Seidl1,2, Dvir Gatt1, Wallace B Wee1
1Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
ERJ open research
|January 16, 2024
概括
在患有原发性纤毛功能障碍的儿童中进行支气管扩展剂反应测试,可以确定那些有更快肺病进展风险的儿童. 这一发现有助于儿童呼吸系统疾病的早期干预.
科学领域:
- 儿科肺病学 儿科肺病学
- 罕见的遗传疾病 罕见的遗传疾病
- 呼吸系统医学 呼吸系统医学
背景情况:
- 初级状动力障碍 (PCD) 通常在儿童中表现为可逆性气道阻塞.
- 支气管扩展剂 (BD) 响应测试在PCD常规螺旋计中的诊断实用性尚未得到充分证实.
研究的目的:
- 为了评估支气管扩展剂反应测试的诊断价值,在患有原发性纤毛功能障碍的儿童.
- 为了确定BD反应测试是否可以预测儿科PCD患者的肺病进展.
主要方法:
- 对患有PCD的儿童肺功能测试结果的回顾性分析.
- 从门诊诊所访问中将螺旋计与BD反应测试 (BD前后测量) 纳入.
- 将BD反应数据与基线和随访螺旋计进行比较,以评估肺功能变化.
主要成果:
- 在患有PCD的儿童中,18.1%的肺功能测试显示出积极的BD反应.
- 阳性BD反应与预测FEV1的百分比从基线到BD前访问的显著绝对变化相关.
- 阳性BD反应的儿童在FEV1预测的年均下降率更大,并且更有可能开始抗菌药物治疗.
结论:
- 患有PCD的儿童对支气管扩展剂的积极反应可能表明加速肺病进展的风险更高.
- BD测试可能是一个有价值的工具,用于识别患有PCD的危险儿科患者.
- 这些发现表明,在PCD管理中,早期治疗干预的可能性很大.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445
Inhaled Medications
271
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
271
Antiasthma Drugs: β2-Adrenoceptor Agonists
267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267
Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K


